CAS number and identifiers (chemical data)

• CAS number: 195875-84-4. PubChem+1

• PubChem CID: 11370864. PubChem

• Other names / synonyms: Tesofensine, NS-2330. PubChem

(These identifiers are stable chemical registry entries and useful when searching chemical catalogs, safety data sheets, or regulatory databases.) PubChem

How Tesofensine works — technical breakdown (mechanism of action)

• Pharmacological class: Tesofensine is a monoamine reuptake inhibitor (MRI) that blocks presynaptic transporters for the three major monoamines: dopamine (DA), norepinephrine (NE), and serotonin (5-HT). This increases the availability of these neurotransmitters at synapses and in brain regions that regulate appetite and energy balance. PubMed+1

• Central effects relevant to weight regulation: By increasing NE and 5-HT signaling in hypothalamic and other brain circuits, tesofensine appears to reduce appetite and food intake and may also increase resting energy expenditure via sympathetic activation in preclinical and clinical studies. PubMed+1

• Pharmacokinetics (summary): Reported oral bioavailability is high; elimination half-life is long (reported in published sources). Metabolism involves hepatic pathways. (See product/compound summaries for full PK detail). PubChem

How Tesofensine works — plain language

• Tesofensine raises brain levels of three “messenger” chemicals — dopamine, norepinephrine and serotonin.

• Those chemicals help regulate hunger, motivation, and how the body uses energy.

• In controlled clinical trials, people taking tesofensine ate less and lost more weight than those on placebo, under the trial conditions. PubMed

Selected clinical evidence (high-priority studies)

• Phase II randomized trial (Astrup et al., Lancet 2008) — In a 24-week, randomized, double-blind, placebo-controlled study in obese patients, tesofensine produced dose-dependent weight loss substantially greater than placebo under study conditions; authors called for further phase-III evaluation. PubMed

• Reviews and evaluations — Several reviews and commentary papers summarize the efficacy signals and safety considerations (e.g., potential increases in heart rate and blood pressure observed in some trial participants). PubMed+1

• Preclinical / mechanistic research — Animal and cellular studies further examine neural circuit actions (e.g., hypothalamic ensembles, effects on feeding circuits) and metabolic effects on energy expenditure. PLOS

Safety, regulatory status, and compliance (FDA / USA-compliant language)

• Regulatory status (USA): Tesofensine is an investigational compound (not an FDA-approved medicine). In the United States, use of tesofensine outside an approved clinical trial or an FDA-authorized program would be non-compliant. Wikipedia

• Safety signals from clinical trials: Clinical studies reported meaningful weight loss but also treatment-emergent increases in heart rate and blood pressure for some participants; these signals were noted in trial reports and require careful evaluation in larger, longer trials. Published reviews summarize these observations and emphasize the need for full phase-III safety data. PubMed+1

• FDA-compliant statement: Tesofensine is not approved by the U.S. Food and Drug Administration (FDA) for treatment of obesity or any other indication. Any claims of safety or efficacy outside peer-reviewed clinical trials would be non-compliant with FDA rules. This summary is for research and educational purposes only. Wikipedia

SEO-optimized description (short for meta/landing page)

Tesofensine (CAS 195875-84-4, PubChem CID 11370864) is an investigational triple monoamine reuptake inhibitor (dopamine / norepinephrine / serotonin) researched for appetite suppression and weight loss. Early clinical trials reported substantial, dose-dependent weight loss in obese patients, but cardiovascular safety signals (increases in heart rate and blood pressure) were observed; tesofensine is not FDA-approved and remains a research compound. PubMed+1

Suggested SEO keyword list (for page metadata & internal linking)

Primary (high volume / targeted):

• Tesofensine, Tesofensine CAS number, Tesofensine research, Tesofensine PubMed, Tesofensine weight loss trial

Secondary (supporting / long-tail):

• NS-2330, triple monoamine reuptake inhibitor, serotonin norepinephrine dopamine reuptake inhibitor, tesofensine mechanism, investigational obesity drug

On-page SEO tips: include exact phrase “Tesofensine (CAS 195875-84-4)” in the meta description and first paragraph; link the words “Lancet 2008 tesofensine trial” to the PubMed trial record; use FAQ schema for the Q&A below to improve chances of rich snippets.

(If you’d like, I can format a meta title and meta description tuned to your site.)

FAQ

Q1 — What is the CAS number for Tesofensine?
A1 — The CAS registry number for Tesofensine is 195875-84-4. Use this identifier when searching chemical catalogs or safety data sheets. PubChem

Q2 — How does Tesofensine work?
A2 — Tesofensine is a monoamine reuptake inhibitor that increases dopamine, norepinephrine and serotonin at nerve synapses; these effects are linked in research studies to reduced appetite and altered energy expenditure. PubMed+1

Q3 — Is Tesofensine FDA-approved for weight loss?
A3 — No. Tesofensine is an investigational drug and is not approved by the FDA. Published clinical trials are phase II; further regulatory review and phase-III data would be required for approval. Wikipedia+1

Q4 — What evidence exists for Tesofensine’s effectiveness?
A4 — A Phase II randomized trial reported dose-dependent weight loss over 24 weeks compared with placebo, supporting further study; however, larger trials are needed to assess long-term efficacy and safety. PubMed

Q5 — What safety issues have been reported?
A5 — Clinical reports noted increases in heart rate and blood pressure with tesofensine in some participants; review papers recommend careful cardiovascular monitoring in future trials. PubMed+1

Q6 — Where can I read the original studies?
A6 — Core references and searchable sources include:

• Astrup A., et al., Effect of tesofensine on bodyweight loss… Lancet 2008 (Phase II trial). PubMed

• Bello NT. Tesofensine: monoamine reuptake inhibitor overview. (review). PubMed

• PubChem entry for compound identifiers and chemical data. PubChem

Selected citations (clickable / for further reading)

• Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008. PubMed

• Doggrell SA. Tesofensine— a novel potent weight loss medicine (evaluation / review). Expert Opin Investig Drugs. 2009. PubMed

• Bello NT. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. (review). PubMed

• PubChem — Tesofensine (CID 11370864) (chemical identifiers and links). PubChem

• Perez CI, et al. Preclinical neural-circuit studies describing tesofensine actions. (PLOS / PMC 2024 example mechanistic paper). PLOS

Compliance reminder

• This summary is for research and educational purposes only and is intentionally written to be FDA-compliant (it does not recommend, endorse, or provide dosing, procurement, or therapeutic instructions for unapproved use). Tesofensine is not an FDA-approved therapy. Any clinical use must occur only under approved clinical trials or regulatory pathways in the relevant jurisdiction.

• NOT FOR HUMAN USE. FOR RESEARCH PURPOSES ONLY